BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
BIOSTEM TECHNOLOGIES NEW (BSEM)
NASDAQ:AMEX Investor Relations:
otcmarkets.com/stock/bsem/news/biostem-technologies-inc--announces-a-pre-clinical-study-of-bsem17-115-at-university-of-miami?id=177750&b=y
Company Research
Source: GlobeNewswire
Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care, announces breakthrough results published in the peer-reviewed journal, International Wound Journal. The study validates the clinical efficacy of BioREtain®-processed placental membranes (RE-AC) compared to the standard of care (SOC). Utilizing a real-world population with large, hard-to-heal, complex chronic diabetic foot ulcers (DFUs), the study demonstrates a clear advantage in 12-week wound healing rates for the RE-AC-treated group compared to the SOC group. Jason Matuszewski, CEO of BioStem Technologies Inc.,
Show less
Read more
Impact Snapshot
Event Time:
BSEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BSEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BSEM alerts
High impacting BIOSTEM TECHNOLOGIES NEW news events
Weekly update
A roundup of the hottest topics
BSEM
News
- BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental AllograftsGlobeNewswire
- BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare GlobalGlobeNewswire
- BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 MillionGlobeNewswire
- BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) RegionsGlobeNewswire
- BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024GlobeNewswire